exebacase + antistaphylococcal antibiotics

**Exebacase + antistaphylococcal antibiotics** is a combination therapy consisting of *exebacase* (CF-301), a recombinantly produced bacteriophage-derived lysin, used alongside standard-of-care antistaphylococcal antibiotics for the treatment of *Staphylococcus aureus* (including MRSA) bloodstream infections and endocarditis. Exebacase rapidly lyses the peptidoglycan cell wall of S. aureus, leading to rapid bactericidal activity, eradication of biofilms, and disruption of bacterial integrity[6][7][8]. In combination, exebacase demonstrates in vitro and in vivo synergy with a broad range of antistaphylococcal antibiotics, including vancomycin and daptomycin, and possibly others such as nafcillin, oxacillin, cefazolin, telavancin, azithromycin, clindamycin, gentamicin, linezolid, levofloxacin, and trimethoprim-sulfamethoxazole[2][3][6]. Mechanistically, exebacase acts as a cell wall hydrolase (lysin), and antistaphylococcal antibiotics act at various targets (e.g., cell wall synthesis, protein synthesis, DNA replication). This combination targets recalcitrant S. aureus infections and biofilm-associated conditions, with promising results shown in earlier clinical trials and preclinical models, though a large phase 3 trial did not meet its primary clinical endpoint[1][8].

Other names

exebacase and antistaphylococcal antibioticsexebacase combination therapy